Tepotinib Plus Gefitinib in Patients With EGFR-Mutant NSCLC With MET Overexpression or Amplification and Acquired Resistance to Previous EGFR Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tepotinib Plus Gefitinib in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer With MET Overexpression or MET Amplification and Acquired Resistance to Previous EGFR Inhibitor (INSIGHT Study): An Open-Label, Phase 1b/2, Multicentre, Randomised Trial
Lancet Respir Med 2020 May 29;[EPub Ahead of Print], YL Wu, Y Cheng, J Zhou, S Lu, Y Zhang, J Zhao, DW Kim, RA Soo, SW Kim, H Pan, YM Chen, CF Chian, X Liu, DSW Tan, R Bruns, J Straub, A Johne, J Scheele, K Park, JCH Yang, INSIGHT InvestigatorsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.